// App-Quantinova.ai

2632 : The PI3K Delta Inhibitor Idelalisib Interferes With Pre-B Cell Receptor Signaling In Acute Lymphoblastic Leukemia (ALL): A New Therapeutic Concept

Researchers

Presenter

  • Nathalie Y. Rosin

Principal Investigators

  • Ekaterina Kim

  • Stefan Koehrer

  • Jan A. Burger

  • Zhiqiang Wang

  • Susan -Brien

  • William G. Wierda

  • Deborah A. Thomas

  • Zeev Estrov

  • Hagop M. Kantarjian

  • Brian Lannutti

  • Richard E. Davis

Medical Centers

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

  • The University of Texas MD Anderson Cancer Center, Department of Neurosurgery, Houston, TX

  • The University of Texas MD Anderson Cancer Center, Department of Lymphoma and Myeloma, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • United States

Companies

  • Gilead Sciences, Inc

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • B cell lymphomas

  • B-cell acute lymphoblastic leukemia

Biomarkers

  • B-cell lymphoma 6

  • Nucleoside diphosphate kinase A

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Granulin precursor

Drug/Treatment

  • Idelalisib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved